Not available
Quote | XOMA Corporation (NASDAQ:XOMA)
Last: | $25.51 |
---|---|
Change Percent: | -0.94% |
Open: | $25.9 |
Close: | $25.51 |
High: | $25.9 |
Low: | $25.41 |
Volume: | 7,231 |
Last Trade Date Time: | 05/17/2024 03:00:00 am |
News | XOMA Corporation (NASDAQ:XOMA)
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2 nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in ...
2024-05-09 07:53:40 ET More on XOMA Day One wins FDA nod for brain cancer therapy, Ojemda Xoma to acquire Kinnate Biopharma for $2.3352 - $2.5879 per share Seeking Alpha’s Quant Rating on XOMA Historical earnings data for XOMA Financial informa...
Message Board Posts | XOMA Corporation (NASDAQ:XOMA)
Subject | By | Source | When |
---|---|---|---|
whytestocks: $XOMA News Article - XOMA to Present at H.C. Wainwright BioConnect Investor Conference | whytestocks | investorshangout | 04/26/2023 7:45:48 PM |
Keeps going up ????? | ison929 | investorshub | 07/15/2022 3:18:04 PM |
Up | highstakes | investorshub | 06/08/2022 11:45:48 AM |
whytestocks: $XOMA News Article - Kuros Biosciences: Completion of the Acquisition of Checkmate Phar | whytestocks | investorshangout | 06/02/2022 2:35:50 PM |
https://abcnews.go.com/Health/antibody-therapies-cut-deaths-reduce-exposure-covi | Preciouslife1 | investorshub | 01/28/2021 1:37:10 PM |
News, Short Squeeze, Breakout and More Instantly...
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:XOMA), the biotech royalty aggregator, announced today that member...
EMERYVILLE, Calif., May 14, 2024 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA), the biotech royalty aggregator, announced today that members of its Executive Team will participate in the H.C. Wainwright 2 nd Annual Bioconnect Investor Conference at NASDAQ being held on May 20, 2024, in ...
Earned $9 million milestone upon U.S. Food and Drug Administration’s approval of Day One’s OJEMDA™ (tovorafenib); XOMA is entitled to receive a mid-single digit royalty on OJEMDA™ sales Acquired Kinnate Pharmaceuticals, adding at least $9.5 million in...